Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
J Card Fail. 2012 May;18(5):351-8. doi: 10.1016/j.cardfail.2012.01.019. Epub 2012 Mar 10.
Copeptin, a stable fragment of the vasopressin prohormone, has been shown to be a significant biomarker for morbidity and mortality in heart failure. The aims of this study were to evaluate the influence of plasma sodium on the prognostic significance of copeptin concentrations in heart failure outpatients and to determine whether increased copeptin concentrations predict future development of hyponatremia.
A total of 340 heart failure patients with left ventricular systolic dysfunction were followed for 55 months (median) in a Danish heart failure clinic. A baseline measurement of plasma copeptin, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and sodium was performed, and the sodium concentrations were recorded during 3 months after the baseline visit in the heart failure clinic. Patients were divided into 3 groups according to copeptin tertiles. In multivariate Cox proportional hazard models adjusted for confounders, including plasma sodium, loop diuretic dose, and NT-proBNP, copeptin was a significant predictor of hospitalization or death (hazard ratio 1.4, 95% confidence interval 1.1-1.9; P < .019) but did not predict mortality independently from NT-proBNP. Additionally, copeptin concentrations did not predict future development of hyponatremia.
Plasma copeptin levels predict mortality in outpatients with chronic heart failure independently from clinical variables, plasma sodium, and loop diuretic doses. Furthermore, copeptin predicts the combined end point of hospitalization or death independently from NT-proBNP.
加压素原的稳定片段copeptin 已被证明是心力衰竭患者发病率和死亡率的重要生物标志物。本研究旨在评估血浆钠对心力衰竭门诊患者 copeptin 浓度预后意义的影响,并确定 copeptin 浓度升高是否可预测低钠血症的发生。
共有 340 名左心室收缩功能障碍的心力衰竭患者在丹麦心力衰竭诊所随访 55 个月(中位数)。在基线时检测血浆 copeptin、N 端脑利钠肽前体(NT-proBNP)和钠,在基线就诊后 3 个月内在心力衰竭诊所记录钠浓度。根据 copeptin 三分位值将患者分为 3 组。在调整混杂因素(包括血浆钠、袢利尿剂剂量和 NT-proBNP)的多变量 Cox 比例风险模型中,copeptin 是住院或死亡的显著预测因子(危险比 1.4,95%置信区间 1.1-1.9;P<.019),但不能独立于 NT-proBNP 预测死亡率。此外,copeptin 浓度不能预测未来低钠血症的发生。
血浆 copeptin 水平可独立于临床变量、血浆钠和袢利尿剂剂量预测慢性心力衰竭门诊患者的死亡率。此外,copeptin 可独立于 NT-proBNP 预测住院或死亡的联合终点。